CA Patent

CA3016642A1 — Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

Assigned to Ferring BV · Expires 2009-08-13 · 17y expired

What this patent protects

The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.

USPTO Abstract

The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.

Drugs covered by this patent

Patent Metadata

Patent number
CA3016642A1
Jurisdiction
CA
Classification
—
Expires
2009-08-13
Drug substance claim
No
Drug product claim
No
Assignee
Ferring BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.